文献速递膀胱癌与上尿路尿路上皮癌

门诊电灼治疗乳头状Ta低级别膀胱癌的长期结局与费用节省

Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
PubMed 文献 · BJU Int · 2024-01-05

这项回顾性研究纳入270例复发、小型、乳头状低级别表现的TaLG NMIBC患者,在随访中接受门诊局部麻醉下电灼治疗。10年癌症特异性死亡率为0%,进展率为3.1%(95%CI 0.8-5.4%),安大略省每例患者直接费用节省估计为6994.14加元。

要点

  • 270例复发TaLG NMIBC患者接受门诊电灼,中位随访10.1年,10年癌症特异性死亡率为0%。
  • 10年疾病进展率为3.1%(95%CI 0.8-5.4%)。
  • 安大略省每例患者直接费用节省估计为6994.14加元。

核心结论

  • 本研究支持经适当选择的复发、表现TaLG的NMIBC患者可在局部麻醉下安全接受门诊电灼治疗,对较大或多发复发肿瘤偶尔行TURBT,不损害长期肿瘤学结局。
  • 作者认为该方式可为医疗系统带来可观费用节省、对患者友好,并可更广泛采用。

研究设计与样本

  • 回顾性研究,纳入521例原发性TaLG NMIBC患者中270例在随访期间因复发、小型、乳头状低级别表现肿瘤接受门诊电灼治疗者,地点为加拿大多伦多大学大学健康网络。
  • 评估癌症特异性死亡率和疾病进展(至MIBC或转移)的累积发生率,以及可能的直接费用节省。

主要发现

  • 270例患者平均(标准差)年龄64.9(13.3)岁,70.8%为男性,60.3%为单发肿瘤。
  • 每例患者平均(标准差,范围)门诊电灼次数为3.1(3.2,1-22)次。
  • 中位(四分位距)随访10.1(5.8-16.2)年。
  • 随访期间患者还平均(标准差)接受3.6(3.0)次TURBT,用于多发或较大复发肿瘤。
  • 44.4%的患者从未接受膀胱内治疗。

临床怎么用

  • 作者认为经适当选择的复发、表现TaLG的NMIBC患者可在局部麻醉下接受门诊电灼治疗,对较大或多发复发肿瘤偶尔行TURBT。
  • 作者认为该方式可更广泛采用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess whether office-based fulguration (OF) under local anaesthesia for small, recurrent, pathological Ta low-grade (LG) non-muscle-invasive bladder cancer (NMIBC) is an effective alternative to transurethral resection of bladder tumour (TURBT), avoiding the costs and risks of procedure, and anesthesia. PATIENTS AND METHODS: Of 521 patients with primary TaLG NMIBC, this retrospective study included 270 patients who underwent OF during follow-up for recurrent, small, papillary LG-appearing tumours at a university centre (University Health Network, University of Toronto, Canada). We assessed the cumulative incidence of cancer-specific mortality (CSM) and disease progression (to MIBC or metastases), as well as possible direct cost savings. RESULTS: In the 270 patients with recurrent TaLG NMIBC treated with OF, the mean (sd) age was 64.9 (13.3) years, 70.8% were men, and 60.3% had single tumours. The mean (sd, range) number of OF procedures per patient was 3.1 (3.2, 1-22). The median (interquartile range) follow-up was 10.1 (5.8-16.2) years. Patients also underwent a mean (sd) of 3.6 (3.0) TURBTs during follow-up in case of numerous or bulkier recurrence. In all, 44.4% of patients never received intravesical therapy. The 10-year incidence of CSM and progression were 0% and 3.1% (95% confidence interval 0.8-5.4%), respectively. Direct cost savings in Ontario were estimated at $6994.14 (Canadian dollars) per patient over the study follow-up. CONCLUSIONS: This study supports that properly selected patients with recurrent, apparent TaLG NMIBC can be safely managed with OF under local anaesthesia with occasional TURBT for larger or numerous recurrent tumours, without compromising long-term oncological outcomes. This approach could generate substantial cost-saving to healthcare systems, is patient-friendly, and could be adopted more widely.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Vitug C, Lajkosz K, Chavarriaga J, et al. Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer. BJU Int. 2024. PMID: 38105525. doi:10.1111/bju.16269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。